Search results
Results from the WOW.Com Content Network
The Tandem Diabetes Care t:Slim X2 was approved by the U.S. Food and Drug Administration in 2019 and is the first insulin pump to be designated as an alternate controller enabled (ACE) insulin pump. ACE insulin pumps allow users to integrate continuous glucose monitors, automated insulin dosing (AID) systems, and other diabetes management ...
Dexcom entered into a partnership in 2015 with Google Life Sciences (which subsequently became Verily) to develop the Dexcom G7 [21] [22] [23]; Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its new G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps.
In November 2011, the company received FDA clearance to market the t:slim Insulin Pump, the first ever touch-screen insulin pump. [10] In February 2013, the company received FDA clearance to market the t:connect Diabetes Management Application, a Mac and PC-compatible data management application that provides t:slim Pump users and their healthcare providers a way to display data from the pump ...
A glitch in a version of Tandem Diabetes Care's Apple iOS app that is used with certain insulin pumps has led to over 200 injuries, prompting the FDA to issue a recall.
Tandem Diabetes' (TNDM) insulin pump seems to be a strategic fit and well-timed from its massive uptake by the diabetic patients in Canada. Tandem Diabetes Signs as an Insulin Pump Vendor in ...
For premium support please call: 800-290-4726 more ways to reach us
An Abbreviated New Drug Application (ANDA) is an application for a U.S. generic drug approval for an existing licensed medication or approved drug. The ANDA is submitted to FDA's Center for Drug Evaluation and Research, Office of Generic Drugs, which provides for the review and ultimate approval of a generic drug product. Once approved, an ...
Pump and infusion set (catheter) placement Insulin basal bolus profile. Insulin pumps are drug delivery devices used to treat patients with type 1 and type 2 diabetes. The Minimed Paradigm REAL-Time and Continuous Glucose Monitoring (CGM) system, which received FDA clearance in 2006, uses tubing and a reservoir with rapid-acting insulin.